The ad_genetic_risk_loci dataset identifies PLCG2 rs72824905 as a rare protective AD variant with a strong protective odds-ratio proxy. The notebook's Enrichr and GTEx analysis places PLCG2 in a microglial immune signaling module with actionable phospholipase biology. Hypothesis: partial, pathway-biased PLCG2 activation can increase microglial plaque and debris clearance while avoiding broad inflammatory gain-of-function toxicity.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["SYK Activation Downstream of TYROBP"]
B["PLCG2 Phosphorylation Tyr753/Tyr759"]
C["PIP2 Hydrolysis IP3 + DAG Generation"]
D["IP3 Receptor ER Ca2+ Release"]
E["DAG/PKC Activation Cytoskeletal Remodeling"]
F["Calcium-Dependent Phagocytic Activity"]
G["Amyloid-beta/Tau Phagocytosis"]
H["P522R Variant Enhanced PLCG2 Activity"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"protective"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
Median TPM across 13 brain regions for PLCG2 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations5 with PMIDValidation: 0%7 supporting / 1 opposing
✓For(7)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
5
MECH 0CLIN 3GENE 5EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
PLCG2 rs72824905 is a protective rare variant in A…
Supporting
GENE
dataset:ad_gene…
-
-
-
-
-
PLCG2 ranked high on druggability due to protectiv…
Supporting
GENE
notebook:gwas-a…
-
-
-
-
-
Genetic variants of phospholipase C-γ2 alter the p…
Protective genetics do not define the safe activation window; inflammatory gain-of-function alleles create tox…▼
Protective genetics do not define the safe activation window; inflammatory gain-of-function alleles create toxicity risk.
notebook:gwas-ad-risk-loci-analysis
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we administer a selective PLCG2 partial agonist (targeting the C-terminal SH3 domain to bias toward PIP2 hydrolysis over inflammatory signaling) to 6-month-old 5xFAD mice via continuous subcutaneous infusion for 8 weeks, THEN cortical amyloid plaque density will decrease by ≥30% (measured by [11C]PiB PET or thioflavin S stereology) and plaque-associated microglia will show ≥2-fold increased CD68+ phagolysosomal area per plaque, while hippocampal IL-1β and TNF-α protein levels will not increase by >50% compared to vehicle-treated controls.
pendingconf: 0.60
Expected outcome: ≥30% reduction in cortical amyloid plaque burden; ≥2-fold increase in microglial phagocytic marker CD68; stable or reduced pro-inflammatory cytokines
Falsified by: Plaque density does not decrease by at least 20%; or IL-1β/TNF-α increase >50%; or mouse survival/body weight decreases significantly indicating toxicity
Method: 5xFAD transgenic mouse model (n≥12 per group), randomized controlled trial with PLCG2 agonist vs vehicle, 8-week treatment, cross-sectional PET and immunohistochemistry endpoints, multiplex cytokine assay
IF we perform single-nucleus RNA-seq on post-mortem prefrontal cortex tissue from heterozygous rs72824905 carriers (n≥12) vs age-matched non-carrier AD cases (n≥24) from the AMP-AD or Religious Orders Study cohort, THEN microglial nuclei from carriers will show significantly increased expression of phagocytosis/lysosomal genes (TREM2, LPL, CLEC7A, CD68) by ≥1.5-fold log2 fold-change, and carrier brains will have ≥25% lower neuritic plaque burden while CSF NfL levels trend lower (p<0.10).
pendingconf: 0.55
Expected outcome: ≥1.5-fold upregulation of microglial clearance gene module; ≥25% lower neuritic plaque density; no elevation of type I interferon response genes
Falsified by: No significant difference in clearance gene expression; instead, increased expression of inflammatory genes (CXCL10, ISG15); or plaque burden equal or higher in carriers
Method: AMP-AD/Release cohort post-mortem brain tissue, single-nucleus RNA-seq (10x Chromium), stratified by rs72824905 genotype, adjusted for age/sex/PMI/AD pathology stage, power ≥80% for 1.5-fold effect
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
PLCG2 — Search for structure
Click to search RCSB PDB